1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

Mid-Stage Milvexian Cleared First Proof-Of-Concept Hurdle

 
• By Mandy Jackson

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

Pharmaceutical research developing genetic medicine
BMS has 64 assets in Phase I and II development • Source: Alamy

Bristol Myers Squibb Company is under pressure to bring new drugs to market before several of its current blockbuster products face generic and biosimilar competition. But in addition to a suite of late-stage and newly approved therapies that it believes will generate more than $25bn in new revenue by 2029, the company has a rapidly growing pipeline of Phase I and II research and development programs with many drug candidates on the cusp of proof-of-concept data or nearing advancement into Phase III.

Bristol showcased some of its early and mid-stage clinical programs that may help BMS grow its revenue base later in this decade and beyond during an investor event on 16 November

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.